Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression

Lancet

Volumn 351, Issue 9097, 1998, Pages 187-188

  Bontkes, Hetty J ^a   Walboomers, Jan M M ^b   Meijer, Chris J L M ^b   Helmerhorst, Theo J M ^b   Stern, Peter L ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; GENE EXPRESSION; HERPES VIRUS; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; PRIORITY JOURNAL; UTERINE CERVIX DYSPLASIA;

EID: 0032539460     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78209-X     Document Type: Article

References (5)

1. 1 Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-27.
2. 2 Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72: 405-11.
3. 3 Remmink AJ, Walboomers JMM, Helmerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995; 61: 306-11.
4. 4 Duggan-Keen MF, Keating PJ, Stevens FRA, et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996; 23: 275-84.
5. 5 Seung S, Urban JL, Schreiber H. A tumour escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 1993; 178: 933-40.